MedTrace Logo

Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma

NCT04567875 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2020-09-29

No results posted yet for this study

Summary

This is a prospective observational study on a cohort of patients with castration-resistant prostate cancer M0, treated with Apalutamide, at the Oncology Unit of the "Andrea Tortora" Hospital of Pagani. Data will be collected on the patient's clinical history and the treatments carried out until the start of therapy with Apalutamide. At that time the study will be described to the patient and informed consent will be given.

In case of a favorable opinion from the patient, the CRF will be filled in. Patients with CRPC M0 treated with Apalutamide, belonging to the Oncology Unit of the Pagani Hospital "Andrea Tortora" and of the other Oncology Units of the ASL of Salerno (Hospital of Vallo della Lucania) will be studied with the possibility of enrollment also from other Centers outside the Salerno ASL.

Conditions

  • Castration-resistant Prostate Cancer

Interventions

OTHER

No Intervention on patients

No Intervention on patients

Sponsors & Collaborators

  • Ospedale Andrea Tortora di Pagani

    lead NETWORK

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-16
Primary Completion
2022-03-31
Completion
2022-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04567875 on ClinicalTrials.gov